1. Levinson, J. E. & Wallace, C. A. Dismantling the pyramid. J. Rheumatol. 33, 6–10 (1992).
2. Tambralli, A. et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J. Rheumatol. 40, 1749–55 (2013).
3. Ravelli, A. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 77, 819–828 (2018).
4. Giancane, G. et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res. Ther. 21, 168 (2019).
5. Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390–392 (2004).